Statins are widely used drugs to lower cholesterol levels and to reduce the risk of cardiovascular disease. However, it has been reported that statins are associated with adverse side effects of skeletal myopathy. Statin treatment can impair mitochondrial function and induce apoptosis in skeletal muscle in both human and animal models. Ubiquinone plays an essential role in transferring electrons in the mitochondrial electron transfer chain for oxidative phosphorylation. However, statin treatment reduces ubiquinone levels in the cholesterol synthesis pathway, which may be associated with mitochondrial dysfunction. In addition, reactive oxygen species (ROS) production and apoptosis induced by statins may provide cellular and molecular mechanisms in skeletal myopathy. Exercise is the most effective therapy to prevent metabolic and cardiovascular diseases. However, whether exercise provides a benefit to or exacerbation of statin-induced myopathy in skeletal muscle remains poorly investigated. This review will briefly provide a comprehensive summary regarding the effects of statins on skeletal myopathy, and discuss the potential mechanisms of statin-induced myopathy and the role of exercise in statin-induced myopathy in skeletal muscle.
INTRODUCTION
3-hydroxy-3-methylgutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are cholesterol-lowering drugs which work by blocking the rate-limiting step in the cholesterol synthesis pathway (Fig. 1) . Stains are the most frequently and widely used medication in the treatment of cardiovascular disease, diabetes, and cancer to reduce cholesterol levels (e.g., LDL-cholesterol) by inhibiting the formation of mevalonate (a precursor to cholesterol), ubiquinone (coenzyme Q), and other compounds [1, 2] . Although statins have a number of beneficial effects including a lipid-lowering effect, improved endothelial function, anti-inflammation, and insulin sensitivity [1, 3] , statins, particularly lipophilic statins (e.g., simvastatin, atorvastatin, cerivastatin, and lovastatin), also cause adverse side effects in skeletal muscle ranging from mild to moderate muscle fatigue, weakness, and pain to fatal rhabdomyolysis [4] [5] [6] . In fact, considering that the occurrence of less adverse side effects is not reported, the incidence of statin-induced myopathy may be 5-10%, and concerns about the safety of statins on skeletal muscle are expected to increase [7] . However, the underlying mechanisms by which statins induce skeletal muscle side effects have not been clearly determined.
Therefore, this review primarily focuses on statin-induced myopathy and the potential mechanisms of statin-associated myopathy. In addition, this review provides an overview of the role of exercise in stain-induced myopathy. Fig. 1 . Cholesterol synthesis pathway and inhibition of statins.
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EFFECTS OF STATINS ON SKELETAL MYOPATHY
Statins, widely prescribed cholesterol-lowering drugs for the treatment of dyslipidemia and cardiovascular disease, are associated with skeletal muscle-related complaints or myopathies. Apoptosis is programmed cell death that is highly regulated and executed via the activation of caspase dependent or independent signaling. In general, apoptosis plays an important role in governing development, growth, and repair in cells [8] . However, excessive apoptosis may be associated with dysfunction, disease, and myopathy in skeletal muscle. It has been reported that statin treatment can induce apoptosis in skeletal muscle in both human [9] [10] [11] [12] and rodent [13] [14] [15] [16] models. For example, simvastatin treatment (5 μM) during 48 hours increased protein levels of proapoptotic protein Bax and apoptosis marker TUNELpositive nuclei in primary human skeletal muscle cells [12] .
Furthermore, Kobayashi et al. [11] showed that cerivastatin treatment (100 μM) during 24-72 hours elevated apoptosis in rhabdomyosarcoma cells from human subjects.
Mitochondria play a central role in regulating homeostasis as well as inducing apoptosis in skeletal muscle. Therefore, mitochondrial dysfunction is associated with the increase in the susceptibility to apoptosis and oxidative stress in skeletal muscle. Previous studies showed that statins might impair mitochondrial function in the skeletal muscles of humans [17] [18] [19] [20] [21] [22] [23] and animals [15, 24] , leading to myopathy. For example, patients with hypercholesterolemia taking simvastatin (80 mg/day) for 8 weeks displayed a decrease in mitochondrial respiratory chain enzyme and citrate synthase activities [20] . Stains also inhibit the synthesis of ubiquinone (coenzyme Q10), a major electron carrier in the mitochondrial respiratory chain [5, 17] . However, statin treatment does not appear to consistently affect mitochondrial function in the whole body. Chung et al. [25] showed that fat oxidation and respiratory exchange ratio (RER) did not change in patients with hypercholesterolemia taking atorvastatin (40 mg/day) for 8 weeks. Table 1 summarizes the effects of statins on the whole body and skeletal myopathy.
POTENTIAL MECHANISMS OF STATIN-INDUCED MYOPATHY
Although numerous studies on statin-associated myopathy have been reported in animals and humans, the molecular Ubiquinone is located in the mitochondrial respiratory chain, where it plays an essential role in transferring electrons from complex I and II to complex III associated with oxidative phosphorylation and energy production [27] . In addition, ubiquinone acts as a potent antioxidant in the inner mitochondrial membrane by scavenging free radicals [28] .
However, it has been shown that statins reduced levels of ubiquinone in muscle and blood (Fig. 2) . ) free radicals are generated from complex I (mainly) and complex III in the electron transport system and changed to hydrogen peroxide (H2O2). It has been recently reported that statin treatment increased oxidative stress in human skeletal muscle cells [12] and fibers [23] (Fig. 3) . For example, we recently found that simvastatin treatment induced mitochondrial oxidative stress as indicated by increases in O2 ㆍ− and H2O2 production as well as impaired oxygen consumption supported by complex I substrates (glutamate + malate) [12] .
In addition, it has been suggested that statin-induced myopathy is associated with apoptosis in skeletal muscle [5, 9, 12, 30] . As mentioned above, statins induce apoptosis in skeletal muscle, which may be an essential factor causing myopathy experienced by patients taking stains. In general, apoptosis is induced through three major apoptotic signaling -driven pathway [31] . However, statin-induced apoptosis in skeletal muscle may be mitochondrial-mediated as indicated by an increase in Bax, release of cytochrome c, active caspase-9, and caspase-3 by statin treatment [12, 30] . In particular, the increase in ROS (e.g., O2 ㆍ− and H2O2) generation with statin treatment may play an important role in opening the mitochondrial permeability transition pore (mPTP), which results in caspase dependent (e.g., cytochrome c and caspase-9) or independent (e.g., apoptosis inducing factor [AIF] and EndoG) apoptosis in skeletal muscle (Fig. 3) , suggesting that statin-induced oxidative stress triggers mitochondrial-mediated apoptosis. For example, Kwak et al. [12] demonstrated that simvastatin treatment induced apoptosis as well as oxidative stress in differentiated skeletal muscle cells.
ROLE OF EXERCISE IN STAIN-INDUCED MYOPATHY: FRIEND OR FOE?
Exercise is regarded as one of the most cost effective ways to prevent metabolic and cardiovascular diseases and is recommended to patients as a lifestyle intervention to sup- decreased cardiorespiratory fitness and muscle citrate synthase activity in obese subjects [36] . In addition, 2 weeks of treadmill exercise increased muscle damage in rats taking cerivastatin (0.5-1.0 mg/kg/day) for 2 weeks [37] . In contrast, 10 weeks of endurance and resistance exercise training did not affect serum CK in hypercholesterolemic patients taking rosuvastatin (10 mg/day) for 20 weeks [40] .
Furthermore, Meador and Huey [42] showed that 4 weeks of wheel running exercise with cerivastatin treatment (1 mg/kg/day) for 2 weeks prevented statin-associated force loss and increased fatigability in mice, suggesting that exercise prior to statin treatment can protect against statin-induced muscle dysfunction. Table 2 shows a summary of studies examining the effects of exercise on statin-induced myopathy in human and animal models. 
